Comparison of natamycin and voriconazole for the treatment of fungal keratitis

Archives of Ophthalmology

Volumn 128, Issue 6, 2010, Pages 672-678

  Prajna, Namperumalsamy V ^a   Mascarenhas, Jeena ^a   Krishnan, Tiruvengada ^a   Reddy, P Ravindranath ^a   Prajna, Lalitha ^a   Srinivasan, Muthiah ^a   Vaitilingam, C M ^a   Hong, Kevin C ^b   Lee, Salena M ^b   McLeod, Stephen D ^b,c   Zegans, Michael E ^d   Porco, Travis C ^b,c   Lietman, Thomas M ^b,c   Acharya, Nisha R ^b,c  

^a ARAVIND EYE CARE SYSTEM   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATAMYCIN; VORICONAZOLE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INDIA; KERATOMYCOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCAR; SPECTACLES; TREATMENT OUTCOME; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; CORNEA; CORNEAL ULCER; DOUBLE-BLIND METHOD; EYE INFECTIONS, FUNGAL; FEMALE; FUNGI; HUMANS; MALE; MIDDLE AGED; MYCOSES; NATAMYCIN; OPHTHALMIC SOLUTIONS; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES; VISUAL ACUITY;

EID: 77953623941     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.102     Document Type: Article

References (36)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ. 2001;79(3):214-221.
2. Srinivasan M, Gonzales CA, George C, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India. Br J Ophthalmol. 1997; 81(11):965-971. (Pubitemid 27493983)
3. Alfonso EC, Cantu-Dibildox J, Munir WM, et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol. 2006;124(7):941-947.
4. Rosa RH Jr, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in south Florida. Ophthalmology. 1994;101(6):1005-1013. (Pubitemid 24183155)
5. Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113(11):1943-1948. (Pubitemid 44635704)
6. Iyer SA, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens. 2006;32(6):267-271. (Pubitemid 44747199)
7. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15(4):321-327.
8. Varaprasathan G, Miller K, Lietman T, et al. Trends in the etiology of infectious corneal ulcers at the F. I. Proctor Foundation. Cornea. 2004;23(4):360-364.
9. Margolis TP, Whitcher JP. Fusarium: a new culprit in the contact lens case. JAMA. 2006;296(8):985-987. (Pubitemid 44285375)
10. Alfonso EC, Miller D, Cantu-Dibildox J, O'Brien TP, Schein OD. Fungal keratitis associated with non-therapeutic soft contact lenses. Am J Ophthalmol. 2006; 142(1):154-155. (Pubitemid 43946809)
11. Prajna NV, John RK, Nirmalan PK, Lalitha P, Srinivasan M. A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br J Ophthalmol. 2003;87(10):1235-1237.
12. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64(18):1997-2020.
13. Cretì A, Esposito V, Bocchetti M, et al. Voriconazole curative treatment for Acremonium species keratitis developed in a patient with concomitant Staphylococcus aureus corneal infection: a case report. In Vivo. 2006;20(1):169-171.
14. Sponsel W, Chen N, Dang D, et al. Topical voriconazole as a novel treatment for fungal keratitis. Antimicrob Agents Chemother. 2006;50(1):262-268.
15. Ozbek Z, Kang S, Sivalingam J, Rapuano CJ, Cohen EJ, Hammersmith KM. Voriconazole in the management of Alternaria keratitis. Cornea. 2006;25(2): 242-244.
16. Bernal MD, Acharya NR, Lietman TM, Strauss EC, McLeod SD, Hwang DG. Outbreak of Fusarium keratitis in soft contact lens wearers in San Francisco. Arch Ophthalmol. 2006;124(7):1051-1053.
17. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis. 2005;40(12):e110-e112.
18. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacother. 2005;6(7):1215-1229.
19. Hernández Prats C, Llinares Tello F, Burgos San Jose A, Selva Otaolaurruchi J, Ordovas Baines JP. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother. 2004;38(3):414-417. (Pubitemid 38235332)
20. Lai TF, Malhotra R, Esmail-Zaden R, Galanopoulas A, Chehade M, Selva D. Use of voriconazole in Scedosporium apiospermum keratitis. Cornea. 2003; 22(4):391-392.
21. Nulens E, Eggink C, Rijs AJ, Wesseling P, Verweij PE. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol. 2003;41(5):2261-2264. (Pubitemid 36576583)
22. Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob Agents Chemother. 2009;53(2):798-799.
23. Ford JG, Agee S, Greenhaw ST. Successful medical treatment of a case of Paecilomyces lilacinus keratitis. Cornea. 2008;27(9):1077-1079.
24. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92(7):871-878. (Pubitemid 351969658)
25. Mehta H, Mehta HB, Garg P, Kodial H. Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis. Indian J Ophthalmol. 2008;56(3):243-245.
26. Lalitha P, Shapiro B, Srinivasan M, et al. Antimicrobial susceptibility of fusarium, aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol. 2007;125(6):789-793. (Pubitemid 46919740)
27. O'Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5(11):877-882.
28. Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol. 2008;126(1):18-22.
29. Lau D, Fedinands M, Leung L, et al. Penetration of voriconazole, 1%, eyedrops into human aqueous humor: a prospective open-label study. Arch Ophthalmol. 2008;126(3):343-346.
30. Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study: a controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994; 101(12):1871-1882.
31. Iacus SM, Porro G. Missing data imputation, matching and other applications of random recursive partitioning. Comput Stat Data Anal. 2007;52(2):773-789. (Pubitemid 47552603)
32. Loh AR, Hong K, Lee S, Mannis M, Acharya NR. Practice patterns in the management of fungal corneal ulcers. Cornea. 2009;28(8):856-859.
33. Shah KB, Wu TG, Wilhelmus KR, Jones DB. Activity of voriconazole against corneal isolates of Scedosporium apiospermum. Cornea. 2003;22(1):33-36. (Pubitemid 36076679)
34. Granados JM, Puerto N, Carrilero MJ. Efficiency of voriconazole in fungal keratitis caused by candida albicans [in Spanish]. Arch Soc Esp Oftalmol. 2004; 79(11):565-568.
35. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431.
36. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl JMed. 2006;355(14):1432-1444.